Since its FDA approval, chimeric antigen receptor (CAR)-T cell therapy is changing the
landscape of the treatment algorithm for relapsed and refractory large cell lymphoma and …

Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data
guiding management are limited. We describe outcomes and features following CAR-T …

In recent years, chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the
treatment landscape for large B cell lymphoma (LBCL), demonstrating remarkable efficacy …

Background Outcomes are poor for patients with large B-cell lymphoma who relapse after
CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly …

Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has transformed the care of
patients with relapsed/refractory large B cell lymphoma (LBCL). However, approximately …

After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab
and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B‐cell lymphoma …

Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-
cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel …

This study retrospectively evaluated the outcome of salvage therapy in 51 patients who
failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B‐cell …

Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in
patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of …

Clinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown
high overall response rates in patients with relapsed/refractory B-cell malignancies. CART19 …